These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38961545)

  • 1. Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Hattori Y; Fujiwara T; Hagimoto H; Kokubun H; Murata S; Makita N; Abe Y; Kubota M; Tohi Y; Tsutsumi N; Shibasaki N; Inoue K; Kawakita M; Yamasaki T
    Int J Urol; 2024 Oct; 31(10):1102-1106. PubMed ID: 38961545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.
    Iyer G; Balar AV; Milowsky MI; Bochner BH; Dalbagni G; Donat SM; Herr HW; Huang WC; Taneja SS; Woods M; Ostrovnaya I; Al-Ahmadie H; Arcila ME; Riches JC; Meier A; Bourque C; Shady M; Won H; Rose TL; Kim WY; Kania BE; Boyd ME; Cipolla CK; Regazzi AM; Delbeau D; McCoy AS; Vargas HA; Berger MF; Solit DB; Rosenberg JE; Bajorin DF
    J Clin Oncol; 2018 Jul; 36(19):1949-1956. PubMed ID: 29742009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
    Rose TL; Harrison MR; Deal AM; Ramalingam S; Whang YE; Brower B; Dunn M; Osterman CK; Heiling HM; Bjurlin MA; Smith AB; Nielsen ME; Tan HJ; Wallen E; Woods ME; George D; Zhang T; Drier A; Kim WY; Milowsky MI
    J Clin Oncol; 2021 Oct; 39(28):3140-3148. PubMed ID: 34428076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine-based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle-invasive bladder cancer cases-Single-center study in Japan.
    Mitsui Y; Okawa M; Hori S; Uetani M; Kasahara M; Yamabe F; Kobayashi H; Nagao K; Nakajima K
    Int J Urol; 2024 Sep; 31(9):1030-1037. PubMed ID: 38819073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: A retrospective analysis of the patient and treatment factors in a single institute.
    Lee KCE; Mui WH; Chan W; Wong CSF; Chu SKP
    Cancer Rep (Hoboken); 2019 Aug; 2(4):e1170. PubMed ID: 32721111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
    Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
    Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.
    Choueiri TK; Jacobus S; Bellmunt J; Qu A; Appleman LJ; Tretter C; Bubley GJ; Stack EC; Signoretti S; Walsh M; Steele G; Hirsch M; Sweeney CJ; Taplin ME; Kibel AS; Krajewski KM; Kantoff PW; Ross RW; Rosenberg JE
    J Clin Oncol; 2014 Jun; 32(18):1889-94. PubMed ID: 24821883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study.
    Koie T; Ohyama C; Hashimoto Y; Hatakeyama S; Yamamoto H; Yoneyama T; Kamimura N
    Int J Clin Oncol; 2013 Aug; 18(4):724-30. PubMed ID: 23011100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
    Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
    J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
    Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
    Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.
    Narayan V; Mamtani R; Keefe S; Guzzo T; Malkowicz SB; Vaughn DJ
    Cancer Res Treat; 2016 Jul; 48(3):1084-91. PubMed ID: 26639198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer.
    Matsubara N; Mukai H; Naito Y; Nezu M; Itoh K
    Asia Pac J Clin Oncol; 2013 Dec; 9(4):310-7. PubMed ID: 23127231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.
    Meleis L; Moore R; Inman BA; Harrison MR
    J Oncol Pharm Pract; 2020 Mar; 26(2):330-337. PubMed ID: 31081469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial Comment to "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".
    Kikuchi E; Hayakawa N
    Int J Urol; 2024 Oct; 31(10):1106. PubMed ID: 39010787
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial Comment on "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".
    Urabe F; Suzuki H; Iwatani K; Kimura T
    Int J Urol; 2024 Oct; 31(10):1107. PubMed ID: 39010790
    [No Abstract]   [Full Text] [Related]  

  • 16. Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
    Funt SA; Lattanzi M; Whiting K; Al-Ahmadie H; Quinlan C; Teo MY; Lee CH; Aggen D; Zimmerman D; McHugh D; Apollo A; Durdin TD; Truong H; Kamradt J; Khalil M; Lash B; Ostrovnaya I; McCoy AS; Hettich G; Regazzi A; Jihad M; Ratna N; Boswell A; Francese K; Yang Y; Folefac E; Herr HW; Donat SM; Pietzak E; Cha EK; Donahue TF; Goh AC; Huang WC; Bajorin DF; Iyer G; Bochner BH; Balar AV; Mortazavi A; Rosenberg JE
    J Clin Oncol; 2022 Apr; 40(12):1312-1322. PubMed ID: 35089812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
    Murasawa H; Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Iwabuchi I; Ogasawara M; Kawaguchi T
    Int J Clin Oncol; 2017 Feb; 22(1):159-165. PubMed ID: 27534866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.
    Siefker-Radtke AO; Dinney CP; Shen Y; Williams DL; Kamat AM; Grossman HB; Millikan RE
    Cancer; 2013 Feb; 119(3):540-7. PubMed ID: 22914978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of neoadjuvant chemotherapy with four cycles of dose-dense MVAC followed by radical cystectomy in Korean patients with muscle-invasive or locally advanced urothelial carcinoma of bladder.
    Park K; Lee HJ; Kim TU; Ryu H; Ki YK; Hong YJ; Nam JK
    Asia Pac J Clin Oncol; 2023 Dec; 19(6):739-746. PubMed ID: 37461246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.
    Plimack ER; Hoffman-Censits JH; Viterbo R; Trabulsi EJ; Ross EA; Greenberg RE; Chen DY; Lallas CD; Wong YN; Lin J; Kutikov A; Dotan E; Brennan TA; Palma N; Dulaimi E; Mehrazin R; Boorjian SA; Kelly WK; Uzzo RG; Hudes GR
    J Clin Oncol; 2014 Jun; 32(18):1895-901. PubMed ID: 24821881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.